Individualized medicine

Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment

Retrieved on: 
Thursday, April 4, 2024
Research, Professional Services, Data Management, Oncology, Technology, Medical Devices, Genetics, Artificial Intelligence, Health Technology, Data Analytics, Science, Biotechnology, Health, Cloud, Algorithm, Individualized medicine, Exact sciences, Disease, Physician, Risk, Patient, Mayo Clinic, DNA, Cancer, Multimedia, Collection, Medical imaging

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients.

Key Points: 
  • Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients.
  • View the full release here: https://www.businesswire.com/news/home/20240404198461/en/
    Initiative advances precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients at the Mayo Clinic Comprehensive Cancer Center (Graphic: Business Wire)
    “This collaboration supports our mission to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment,” said Kevin Conroy , chairman and chief executive officer, Exact Sciences.
  • The Riskguard hereditary cancer test helps patients and their physicians understand the patients' hereditary risk of cancer.
  • “It will also lead to new scientific and clinical discoveries by Mayo Clinic Comprehensive Cancer Center and Mayo Clinic's Center for Individualized Medicine .”
    Patients will consent to have the tests performed and to have the data shared with Mayo Clinic.

Illumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients

Retrieved on: 
Monday, November 13, 2023
DNA, Partnership, Cardiovascular disease, Education, Genomics, Clinical Pharmacogenetics Implementation Consortium, Personalized medicine, Henry Ford Health, Food and Drug Administration, Genetic distance, Individualized medicine, Lisa, Pharmacist, Henry Ford, Patient, Standard of care, Risk, Physician, SAN, Illumina, Inc., Division, WGS, Diagnosis, Research, Health, American College, Death, Food, World Health Organization, Pharmaceutical industry, Illumina

SAN DIEGO, April 11, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Henry Ford Health, a not-for-profit health care organization in the Detroit metro area, today announced the launch of a partnership to assess the impact of comprehensive genomic testing in cardiovascular disease. The first study under this new partnership, CardioSeq, launches today and will include 1500 patients receiving care from the Division of Cardiovascular Medicine at Henry Ford.

Key Points: 
  • The first study under this new partnership, CardioSeq, launches today and will include 1500 patients receiving care from the Division of Cardiovascular Medicine at Henry Ford.
  • "This study is the first of several that will measure the impact of whole-genome sequencing in patients with cardiovascular disease," said Dr. David Lanfear , vice president of clinical and translational research at Henry Ford Health and the study's lead clinician.
  • Dr. Phil Febbo, chief medical officer of Illumina, added: "We are honored to partner with Henry Ford Health to assess the potential benefits of integrating genomic testing within specialized care centers in the health care system.
  • The CardioSeq study will use an accredited clinical test developed by Illumina that employs WGS to create a comprehensive cardiovascular genomic profile.

Precision Medicine Asia and National Cancer Center Hospital East Announce the Initiation of the LC-SCRUM-AP Genomic Screening Platform for the Asia-Pacific Region

Retrieved on: 
Wednesday, December 21, 2022
Precision medicine, Lung cancer, Cancer, Individualized medicine, MET, RET, KRAS, NGS, Organization, ALK, Patient, National Cancer Center, Medicine, Therapy, HER2, Large-cell lung carcinoma, ROS1, Journal of Thoracic Oncology, BRAF, Antibiotics, Electronic component, News, EGFR

TOKYO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Precision Medicine Asia Co., Ltd. (“PREMIA”) and National Cancer Center Hospital East (“NCCHE”) announced the initiation of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Pacific (LC-SCRUM-AP), a genomic screening platform, which will be integrated with LC-SCRUM-Asia to create an international, large scale lung cancer clinicopathological genomic database for the region.

Key Points: 
  • TOKYO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Precision Medicine Asia Co., Ltd. (“PREMIA”) and National Cancer Center Hospital East (“NCCHE”) announced the initiation of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Pacific (LC-SCRUM-AP), a genomic screening platform, which will be integrated with LC-SCRUM-Asia to create an international, large scale lung cancer clinicopathological genomic database for the region.
  • LC-SCRUM-AP is a genomic screening platform for patients with advanced or recurrent non-small cell lung cancer.
  • The aim is to further develop precision medicine in Asia by establishing a genomic screening infrastructure for the Asia-Pacific region.
  • The integration of the LC-SCRUM-Asia and LC-SCRUM-AP databases will create an international, large-scale lung cancer clinicopathological database and contribute to the development of precision medicine in Asia.

HealthTrackRx Announces the Formation of Clinical Advisory Board with Leading Experts in Infectious Disease and Antimicrobial Resistance

Retrieved on: 
Thursday, October 13, 2022
Doctor of Pharmacy, Laboratory, Mayo Clinic, Infection, COVID, FACP, Tufts University, Pharmacist, Infectious Diseases Society of America, PCR, University, Treatment, Health, Society of Infectious Diseases Pharmacists, Pathology, Molecule, FCCP, AMR, Transplant, Individualized medicine, P, Industry, ARUP Laboratories, MHS, MACP, Summa Health, Duke University, Northeast Ohio Medical University, Society, NIH, Immunodeficiency, IDSA, ID, Master of Science, Dedicated hosting service, ASCP, Community-acquired pneumonia, Patient, American Society for Microbiology, Doctor of Philosophy, Research, Associate, Center, Pharmaceutical industry, Vaccine, Medicine, Microbiology, FIDSA, MD

DENTON, Texas, Oct. 13, 2022 /PRNewswire/ --HealthTrackRx, the nation's premier PCR diagnostic testing laboratory, today announced the formation of its Clinical Advisory Board, comprising of leading clinical experts who specialize in infectious disease (ID) and antimicrobial resistance (AMR).

Key Points: 
  • DENTON, Texas, Oct. 13, 2022 /PRNewswire/ --HealthTrackRx, the nation's premier PCR diagnostic testing laboratory, today announced the formation of its Clinical Advisory Board, comprising of leading clinical experts who specialize in infectious disease (ID) and antimicrobial resistance (AMR).
  • "We are thrilled to have these world-renowned infectious disease and antimicrobial resistance experts on our Clinical Advisory Board.
  • Insights from our Clinical Advisory Board members can help us transform infectious disease diagnostics to improve patient care, reduce healthcare costs, and combat the looming threat of antimicrobial resistance."
  • HealthTrackRx is the nation's leading PCR-based infectious disease laboratory, delivering industry-leading testing turnaround times to healthcare providers nationwide.

Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology

Retrieved on: 
Tuesday, May 24, 2022
Department, MRD, DNA, Disease, Blood, Mayo Clinic, Pathology, Survival, Individualized medicine, Breast cancer, Multimedia, Patient, Genetic testing, NASDAQ, Health, Medical laboratory, NTRA, Department of Oncology, University of Cambridge, Form 10-K, Georgetown University Medical Center, Research, FDA, Recurrence, Thomas Jefferson University, Center, Mayo, Genomics, Biomarker, Alliance for Clinical Trials in Oncology, Clinical Laboratory, CLIA, Therapy, CMO, SEC, Cancer, Laboratory, ISO, Princeton University, Risk, Neoplasm, Medical imaging, Medical device, Natera

AUSTIN, Texas, May 24, 2022 /PRNewswire/ --Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology.

Key Points: 
  • AUSTIN, Texas, May 24, 2022 /PRNewswire/ --Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology.
  • "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera.
  • Dr. Liu most recently served as professor of oncology and chair of research in the Department of Oncology at Mayo Clinic in Rochester, MN.
  • Natera is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health.

United States Hospital Facilities Market Analysis Report 2022-2030 Patient Service (Inpatient, Outpatient), & Service Type (Acute Care, Cardiovascular) - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 14, 2022
Hospitals, Health, Surgery, Cardiology, Neurology, American Hospital Association, Population, CDC, COVID-19, Heart failure, Degenerative disease, Research, Center, Medicine, Hospital, CAGR, HCUP, Machine learning, Lists of diseases, Patient, AHA, Health maintenance organization, Mayo Clinic, Lurie Children's Hospital, Pediatric emergency medicine, Tempus, Health care, Cardiology, Income, USD, Individualized medicine, Prevalence, Health insurance

The "U.S. Hospital Facilities Market Size, Share & Trends Analysis Report by Patient Service (Inpatient, Outpatient), by Service Type (Acute Care, Cardiovascular), by Facility Type, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Hospital Facilities Market Size, Share & Trends Analysis Report by Patient Service (Inpatient, Outpatient), by Service Type (Acute Care, Cardiovascular), by Facility Type, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • According to the American Hospital Association (AHA), there were more than 36.2 million patients admitted to U.S. hospitals, in 2021.
  • Hospitals provide treatment for a variety of indications, including neurology, cardiology, infectious disorders, gastrointestinal diseases, and psychiatric disorders.
  • The cardiovascular service type segment dominated the market in 2021 due to changing & sedentary lifestyles and the increased geriatric & obese population.

Mayo Clinic Collaborates With Personalis Inc. to Expand Cancer Genomic Testing

Retrieved on: 
Tuesday, October 12, 2021
Oncology, Health, Hospitals, Genetics, Pharmaceutical, Biotechnology, Mouse Models of Human Cancer database, Twitter, Efficiency, Health, Individualized medicine, College of American Pathologists, College, Genomics, Department, COVID-19, Clinical Laboratory Improvement Amendments, Culture, Growth, Cancer, Education, Genome, Liu v. Securities and Exchange Commission, Mayo Clinic Cancer Center, PSNL, Mayo Clinic, Pathology, Medicine, Immune system, Mayo, Forecasting, Medical laboratory, National, Veteran, Leadership, Chief Justice of Hungary, U.S. Securities and Exchange Commission, Patient, Research, Coronavirus, National Cancer Institute, Risk, Nasdaq, Center, Veterans' affairs, Pharmaceutical industry, Mayo Clinic, Mayo Clinic Cancer Center, Personalis Inc., MAYO CLINIC, MAYO CLINIC CANCER CENTER, PERSONALIS INC.

Mayo Clinic Cancer Center , Mayo Clinic's Department of Laboratory Medicine and Pathology , and Mayo Clinic's Center for Individualized Medicine are collaborating with Personalis Inc. (Nasdaq: PSNL), a cancer genomics company whose clinical-grade, comprehensive cancer genomic test includes sequencing the entire coding genome through whole-exome and transcriptome sequencing.

Key Points: 
  • Mayo Clinic Cancer Center , Mayo Clinic's Department of Laboratory Medicine and Pathology , and Mayo Clinic's Center for Individualized Medicine are collaborating with Personalis Inc. (Nasdaq: PSNL), a cancer genomics company whose clinical-grade, comprehensive cancer genomic test includes sequencing the entire coding genome through whole-exome and transcriptome sequencing.
  • , executive director of Mayo Clinic Cancer Programs and director of Mayo Clinic Cancer Center.
  • "We are honored to work with Mayo Clinic to increase access to advanced cancer testing," says Richard Chen, M.D., chief medical officer of Personalis.
  • Designated as a comprehensive cancer center by the National Cancer Institute , Mayo Clinic Cancer Center is defining new boundaries in possibility, focusing on patient-centered care, developing novel treatments, training future generations of cancer experts, and bringing cancer research to communities.